Correspondence on ‘2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis’ by Joanna C Robson et al and ‘2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis’ by Ravi Suppiah et al

The new classification criteria for antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitides (AAV) have been eagerly anticipated since the publication of the provisional criteria in 2017 and thus they are quite welcomed. Limitations of the previous criteria used for these conditions include the low sensitivity of the 1990 American College of Rheumatology (ACR) classification criteria, the fact that the patient’s ANCA status had not been included, that there were no previous classification criteria for microscopic polyangiitis (MPA), and the fact that the number of criteria rather than a weighted criteria were used. Furthermore, there was lack of satisfaction among professionals about the 1990 ACR criteria.5

In conclusion, the new criteria for AAV, particularly for MPA and GPA, have good performance in a Latin-American population, mainly constituted by Mestizo patients, with comparable findings to those from Suppiah et al and Robson et al. We think many Latin-American centres as ours could be considered for new studies and protocols addressed by DCVAS and thus reduce the knowledge gap about AAV in this region.

Víctor Román Pimentel-Quiróz 1, 2, Manuel Francisco Ugarte-Gil 1, 2, Graciela S Alarcón 1

1Department of Rheumatology, Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru
3Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Lima, Peru
3Department of Medicine, Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.

Correspondence to Dr Victor Román Pimentel-Quiróz, Universidad Científica del Sur, Sur, Lima, Lima, Peru; victorppq4@gmail.com

Twitter Victor Román Pimentel-Quiróz @VictorioPQ and Manuel Francisco Ugarte-Gil @mugartegil

Contributors All authors contributed equally to this work.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval This study does not involve human participants.

Provenance and peer review Commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

To cite Pimentel-Quiróz VR, Ugarte-Gil MF, Alarcón GS. Ann Rheum Dis Epub ahead of print: [please include Day Month Year]. doi:10.1136/annrheumdis-2022-222317

Received 13 February 2022
Accepted 15 February 2022

http://dx.doi.org/10.1136/annrheumdis-2022-222362


ORCID iDs Victor Román Pimentel-Quiróz http://orcid.org/0000-0002-3638-7054
Manuel Francisco Ugarte-Gil http://orcid.org/0000-0003-1728-1999
Graciela S Alarcón http://orcid.org/0000-0001-5190-9175

REFERENCES

Table 1 Sensitivity and specificity of the new classification criteria for MPA and GPA in the derivation and validation studies and in the Almenara vasculitides cohort

<table>
<thead>
<tr>
<th></th>
<th>Pimentel-Quiróz et al 1,2</th>
<th>Suppiah et al 3</th>
<th>Robson et al 2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MPA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sensitivity</td>
<td>87.0 %</td>
<td>91.0%</td>
<td>NA</td>
</tr>
<tr>
<td>Specificity</td>
<td>93.5%</td>
<td>94.0%</td>
<td>NA</td>
</tr>
<tr>
<td><strong>GPA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sensitivity</td>
<td>80.5%</td>
<td>NA</td>
<td>93.0%</td>
</tr>
<tr>
<td>Specificity</td>
<td>96.2%</td>
<td>NA</td>
<td>94.0%</td>
</tr>
</tbody>
</table>

MPA, Microscopic polyangiitis; GPA, Granulomatosis with polyangiitis; NA, not applicable;